Effects of a Diabetes Prevention Program on Type 2 Diabetes Risk Factors and Quality of Life Among Latino Youths With Prediabetes: A Randomized Clinical Trial.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
15
9
2022
Statut:
epublish
Résumé
Latino youths are disproportionately impacted by prediabetes and type 2 diabetes (T2D). Lifestyle intervention is the first-line approach for preventing or delaying T2D among adults with prediabetes. To assess the efficacy of a diabetes prevention program among Latino youths aged 12 to 16 years with prediabetes. This 2-group parallel randomized clinical trial with 2:1 randomization assessed a lifestyle intervention against usual care among Latino youths with prediabetes and obesity with 6- and 12-month follow-up. The study was conducted at YMCA facilities in Phoenix, Arizona from May 2016 to March 2020. Participants were randomized to lifestyle intervention (INT) or usual care control (UCC). The 6-month INT included 1 d/wk of nutrition and health education and 3 d/wk of physical activity. UCC included 2 visits with a pediatric endocrinologist and a bilingual, bicultural registered dietitian to discuss diabetes risks and healthy lifestyle changes. Insulin sensitivity, glucose tolerance, and weight-specific quality of life (YQOL-W) at 6- and 12-month follow-up. A total of 117 Latino youths (mean [SD] age, 14 [1] years; 47 [40.1%] girls) were included in the analysis. Overall, 79 were randomized to INT and 38 to UCC. At 6 months, the INT led to significant decreases in mean (SE) 2-hour glucose (baseline: 144 [3] mg/dL; 6 months: 132 [3] mg/dL; P = .002) and increases in mean (SE) insulin sensitivity (baseline: 1.9 [0.2]; 6 months: 2.6 [0.3]; P = .001) and YQOL-W (baseline: 75 [2]; 6 months: 80 [2]; P = .006), but these changes were not significantly different from UCC (2-hour glucose: mean difference, -7.2 mg/dL; 95% CI, -19.7 to 5.3 mg/dL; P for interaction = .26; insulin sensitivity: mean difference, 0.1; 95% CI, -0.7 to 0.9; P for interaction = .79; YQOL-W: mean difference, 6.3; 95% CI, -1.1 to 13.7; P for interaction = .10, respectively). Both INT (mean [SE], -15 mg/dL [4.9]; P = .002) and UCC (mean [SE], -15 mg/dL [5.4]; P = .005) had significant 12-month reductions in 2-hour glucose that did not differ significantly from each other (mean difference, -0.3; 95% CI, -14.5 to 14.1 mg/dL; P for interaction = .97). At 12 months, changes in mean (SE) insulin sensitivity in INT (baseline: 1.9 [0.2]; 12 months: 2.3 [0.2]; P = .06) and UCC (baseline: 1.9 [0.3]; 12 months: 2.0 [0.2]; P = .70) were not significantly different (mean difference, 0.3; 95% CI, -0.4 to 1.0; P for interaction = .37). At 12 months, YQOL-W was significantly increased in INT (basline: 75 [2]; 12 months: 82 [2]; P < .001) vs UCC (mean difference, 8.5; 95% CI, 0.8 to 16.2; P for interaction = .03). In this randomized clinical trial, both INT and UCC led to similar changes in T2D risk factors among Latino youths with diabetes; however, YQOL-W was improved in INT compared with UCC. Diabetes prevention interventions that are effective in adults also appeared to be effective in high risk youths. ClinicalTrials.gov Identifier: NCT02615353.
Identifiants
pubmed: 36094502
pii: 2795971
doi: 10.1001/jamanetworkopen.2022.31196
pmc: PMC9468887
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Banques de données
ClinicalTrials.gov
['NCT02615353']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2231196Subventions
Organisme : NIMHD NIH HHS
ID : P20 MD002316
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK134978
Pays : United States
Organisme : NIMHD NIH HHS
ID : L60 MD003594
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK127015
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK107579
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Diabetes Care Educ Newsl. 2012 Summer;33(4):4-7
pubmed: 26451082
JAMA. 2019 Dec 24;322(24):2389-2398
pubmed: 31860047
Diabetes Care. 2019 Jan;42(Suppl 1):S148-S164
pubmed: 30559239
Pediatr Diabetes. 2010 Sep;11(6):417-23
pubmed: 19912553
J R Soc Med. 2011 Dec;104(12):510-20
pubmed: 22179294
J Pediatr. 2012 Jun;160(6):911-7
pubmed: 22217471
Diabetes Educ. 2013 Jan-Feb;39(1):109-18
pubmed: 23150531
J Clin Endocrinol Metab. 2004 Mar;89(3):1096-101
pubmed: 15001593
Exerc Sport Sci Rev. 2015 Jan;43(1):41-7
pubmed: 25390295
N Engl J Med. 1988 Dec 8;319(23):1500-6
pubmed: 3054559
J Pediatr. 2012 Jul;161(1):51-7
pubmed: 22325254
Obesity (Silver Spring). 2007 Nov;15(11):2553-6
pubmed: 18070745
JAMA Pediatr. 2020 Feb 1;174(2):e194498
pubmed: 31790544
Diabetes Care. 2005 Apr;28(4):902-9
pubmed: 15793193
Annu Rev Psychol. 2009;60:549-76
pubmed: 18652544
JAMA. 2021 Aug 24;326(8):717-727
pubmed: 34427600
Diabetes Care. 2009 Jan;32(1):45-7
pubmed: 18840769
Qual Life Res. 2011 Aug;20(6):961-8
pubmed: 21188537
Diabetes Care. 2021 Nov;44(11):2457-2459
pubmed: 34670795
Diabetes Care. 2014 Feb;37(2):317-24
pubmed: 24062325
Prev Med Rep. 2019 Mar 04;14:100840
pubmed: 30911460
Diabetes. 1980 Jan;29(1):41-9
pubmed: 7380107
Int J Surg. 2011;9(8):672-7
pubmed: 22019563
JAMA. 2019 Nov 5;322(17):1707-1708
pubmed: 31566652
JAMA. 2003 Oct 8;290(14):1884-90
pubmed: 14532317
Trials. 2020 Aug 14;21(1):716
pubmed: 32799920
Implement Sci. 2015 Dec 15;10:172
pubmed: 26670418
Milbank Q. 2020 Mar;98(1):172-196
pubmed: 31994260
J Clin Endocrinol Metab. 2008 Nov;93(11):4231-7
pubmed: 18713820
Curr Diab Rep. 2020 Aug 28;20(10):51
pubmed: 32857299
Diabetes. 2012 Mar;61(3):606-14
pubmed: 22315322
Diabetes. 2005 Aug;54(8):2404-14
pubmed: 16046308
Qual Life Res. 2011 Mar;20(2):215-24
pubmed: 20820926
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Nat Rev Endocrinol. 2013 Oct;9(10):607-14
pubmed: 23897171
Diabetes Care. 2021 Dec;44(12):2691-2698
pubmed: 34607833
MMWR Suppl. 2016 Jul 08;65(3):1-3
pubmed: 27389046
J Clin Endocrinol Metab. 2020 Feb 1;105(2):
pubmed: 31972003
J Behav Med. 2009 Feb;32(1):89-105
pubmed: 19101788
BMJ Clin Evid. 2011 Apr 04;2011:
pubmed: 21463538
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
BMC Public Health. 2017 Mar 16;17(1):261
pubmed: 28302101
Res Q Exerc Sport. 2004 Sep;75(3):259-71
pubmed: 15487290
Diabetes Educ. 2012 Jul-Aug;38(4):504-12
pubmed: 22585870
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
J Pediatr. 2020 Apr;219:11-22
pubmed: 32143933
Depress Anxiety. 2017 Oct;34(10):866-876
pubmed: 28370947
Obesity (Silver Spring). 2018 Dec;26(12):1856-1865
pubmed: 30426694
Curr Probl Pediatr Adolesc Health Care. 2019 Jan;49(1):16-22
pubmed: 30567629
Contemp Clin Trials. 2018 Dec;75:19-28
pubmed: 30342256
Front Public Health. 2013 Aug 23;1:29
pubmed: 24350198